{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T09:37:42Z","timestamp":1696412262429},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2015,12,9]],"date-time":"2015-12-09T00:00:00Z","timestamp":1449619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0144004","type":"journal-article","created":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T01:21:27Z","timestamp":1449710487000},"page":"e0144004","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection"],"prefix":"10.1371","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct01132313","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Tarik","family":"Asselah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Bronowicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ansgar W.","family":"Lohse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beat","family":"M\u00fcllhaupt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Schuchmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bourli\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart K.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward J.","family":"Gane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry O.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Voss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Baum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John-Paul","family":"Gallivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wulf O.","family":"B\u00f6cher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico J.","family":"Mensa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,12,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"JG McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C infection","volume":"364","author":"IM Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"F Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"EJ Gane","year":"2013","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"F Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"e55285","DOI":"10.1371\/journal.pone.0055285","article-title":"Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting","volume":"8","author":"B Maasoumy","year":"2013","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1053\/j.gastro.2011.08.051","article-title":"Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection","volume":"141","author":"S Zeuzem","year":"2011","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"ref8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/liv.12423","article-title":"HCV direct-acting antiviral agents: the best interferon-free combinations","volume":"34","author":"R Schinazi","year":"2014","journal-title":"Liver Int"},{"key":"ref9","unstructured":"AASLD\/IDSA\/IAS\u2013USA. Recommendations for testing, managing, and treating hepatitis C. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.hcvguidelines.org\" xlink:type=\"simple\">http:\/\/www.hcvguidelines.org<\/ext-link>. Accessed 21 March 2015."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2014.10.044","article-title":"Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry","volume":"62","author":"PJ Ruane","year":"2015","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature08825","article-title":"ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C","volume":"464","author":"J Fellay","year":"2010","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1053\/j.gastro.2010.06.016","article-title":"Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction","volume":"139","author":"A Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1053\/j.gastro.2010.06.071","article-title":"ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy\u2014a genome-wide study of Japanese HCV virus patients","volume":"139","author":"H Ochi","year":"2010","journal-title":"Gastroenterology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1053\/j.gastro.2010.12.038","article-title":"Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function","volume":"140","author":"Y Hitomi","year":"2011","journal-title":"Gastroenterology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2010.06.007","article-title":"Unraveling the genetic predispostition of ribavirin-induced anemia","volume":"53","author":"T Asselah","year":"2010","journal-title":"J Hepatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa1213557","article-title":"Faldaprevir and deleobuvir for HCV genotype 1 Infection","volume":"369","author":"S Zeuzem","year":"2013","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"JJ Feld","year":"2014","journal-title":"N Engl J Me"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"P Ferenci","year":"2014","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/S0140-6736(15)60159-3","article-title":"Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial","volume":"385","author":"C H\u00e9zode","year":"2015","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/hep.26096","article-title":"Anemia during treatment with peginterferon alfa-2b\/ribavirin and boceprevir: analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial","volume":"57","author":"MS Sulkowski","year":"2013","journal-title":"Hepatology"},{"key":"ref21","article-title":"STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon\/ribavirin for chronic HCV genotype-1 infection","author":"P Ferenci","year":"2015","journal-title":"J Hepatol"},{"key":"ref22","unstructured":"Background materials for Boceprevir Advisory Committee, Division of Antiviral Products (DAVP), April 27, 2011. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/drugs\/AntiviralDrugsAdvisoryCommittee\/ucm252341.pdf\" xlink:type=\"simple\">http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/drugs\/AntiviralDrugsAdvisoryCommittee\/ucm252341.pdf<\/ext-link>. Accessed 20 April 2015."},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1002\/hep.27022","article-title":"ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response","volume":"59","author":"JA Holmes","year":"2014","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/infdis\/jir210","article-title":"IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C","volume":"204","author":"K Chayama","year":"2011","journal-title":"J Infect Dis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jhep.2013.05.017","article-title":"Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy","volume":"59","author":"E Ogawa","year":"2013","journal-title":"J Hepatol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","article-title":"Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus","volume":"139","author":"AJ Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jhep.2012.05.016","article-title":"Genomics and HCV infection: progression of fibrosis and treatment response","volume":"57","author":"E Estrabaud","year":"2012","journal-title":"J Hepatol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"N Afdhal","year":"2014","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0144004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T12:44:31Z","timestamp":1540039471000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0144004"}},"subtitle":[],"editor":[{"given":"Jose Ignacio","family":"Herrero","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,12,9]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,12,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0144004","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,9]]}}}